

Selpercatinib (RETEVMO) Criteria for Use December 2022

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at www.pbm.va.gov or [PBM INTRAnet](#) for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive selpercatinib.

- Symptomatic CNS metastases
- GFR < 30 mL/min
- Uncontrolled hypertension
- Baseline QTc >470 msec
- Strong or Moderate CYP3A4 inducers[^]
- Pregnancy (i.e. known pregnancy or positive pregnancy test)
- Breastfeeding

[^]See package labeling for dosing with concomitant Strong or Moderate CYP3A inhibitors or concomitant acid reducing drugs

Inclusion Criteria

The answer to ONE the following must be fulfilled in order to meet criteria:

- Locally Advanced or Metastatic non-small cell lung cancer with a RET gene fusion
- Advanced or Metastatic Medullary Thyroid Cancer (MTC) with a RET mutation requiring systemic therapy
- Advanced or Metastatic Thyroid Cancer with a RET gene fusion requiring systemic therapy who are radioactive iodine-refractory (if radioactive iodine is appropriate)
- Advanced or Metastatic solid tumors with a RET gene fusion that progressed on or following prior therapy or who have no satisfactory alternative treatment options

Additional Inclusion Criteria

The answers to the following must be fulfilled in order to meet criteria.

- Care is provided by a VA/VA purchased care oncology provider
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Goals of care and role of Palliative Care consult have been discussed and documented

Additional Inclusion Criteria- Select if applicable

- For patients who can become pregnant and patients with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 1 week after stopping treatment

Other Justification

Prepared: November 2020; Rev December 2022. Contact: Mark C. Geraci, Pharm.D., BCOP, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services 10P4P
